Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by equities researchers at Leerink Swann from a “market perform” rating to an “outperform” rating in a research report issued on Tuesday, reports. The firm currently has a $445.00 price target on the stock, up from their previous price target of $270.00. Leerink Swann’s price target indicates a potential upside of 87.62% from the stock’s previous close.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 10,000 shares of Intercept Pharmaceuticals stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total transaction of $2,267,200.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 16.59% on Tuesday, hitting $276.52. The stock had a trading volume of 6,088,050 shares. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock has a 50-day moving average of $232.6 and a 200-day moving average of $291.7. The company’s market cap is $5.831 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-14.82 EPS for the current fiscal year.

ICPT has been the subject of a number of other recent research reports. Analysts at Deutsche Bank upgraded shares of Intercept Pharmaceuticals to an “outperform” rating in a research note on Tuesday. They now have a $500.00 price target on the stock, up previously from $395.00. Separately, analysts at Nomura upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 29th. They now have a $323.00 price target on the stock. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $503.00.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.